MX2017010577A - Dosis de panobinostat para el mieloma multiple. - Google Patents

Dosis de panobinostat para el mieloma multiple.

Info

Publication number
MX2017010577A
MX2017010577A MX2017010577A MX2017010577A MX2017010577A MX 2017010577 A MX2017010577 A MX 2017010577A MX 2017010577 A MX2017010577 A MX 2017010577A MX 2017010577 A MX2017010577 A MX 2017010577A MX 2017010577 A MX2017010577 A MX 2017010577A
Authority
MX
Mexico
Prior art keywords
panobinostat
multiple myeloma
dosages
bortezomib
safety
Prior art date
Application number
MX2017010577A
Other languages
English (en)
Inventor
Ling Rong
Mu Song
Paul Sofia
GRAZIOLI Laura
Capdeville Renaud
Binlich Florence
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55405393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017010577(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017010577A publication Critical patent/MX2017010577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Tratamiento de mieloma múltiple con una combinación de panobinostat y bortezomib con dosis especificadas ajustadas para la seguridad.
MX2017010577A 2015-02-19 2016-02-17 Dosis de panobinostat para el mieloma multiple. MX2017010577A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118254P 2015-02-19 2015-02-19
US201562119571P 2015-02-23 2015-02-23
PCT/IB2016/050850 WO2016132303A1 (en) 2015-02-19 2016-02-17 Panobinostat dosages for multiple myeloma

Publications (1)

Publication Number Publication Date
MX2017010577A true MX2017010577A (es) 2017-12-07

Family

ID=55405393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010577A MX2017010577A (es) 2015-02-19 2016-02-17 Dosis de panobinostat para el mieloma multiple.

Country Status (19)

Country Link
US (3) US20190388393A1 (es)
EP (1) EP3258933A1 (es)
JP (2) JP2018507216A (es)
KR (1) KR20170118798A (es)
CN (1) CN107249596A (es)
AU (2) AU2016221327A1 (es)
BR (1) BR112017017594A2 (es)
CA (1) CA2976755A1 (es)
CL (1) CL2017002116A1 (es)
IL (1) IL253895A0 (es)
MA (1) MA41544A (es)
MX (1) MX2017010577A (es)
PH (1) PH12017501494A1 (es)
RU (1) RU2729425C2 (es)
SG (1) SG11201706521XA (es)
TN (1) TN2017000356A1 (es)
TW (1) TW201630602A (es)
WO (1) WO2016132303A1 (es)
ZA (1) ZA201705363B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314222B (zh) * 2019-08-07 2023-05-26 上海交通大学医学院附属瑞金医院 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221126A1 (en) * 2005-08-03 2008-09-11 Atadja Peter W Use of Hdac Inhibitors for the Treatment of Myeloma
EP2032531B1 (en) 2006-06-12 2016-02-10 Novartis AG Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
RU2009134223A (ru) * 2007-02-15 2011-03-20 Новартис АГ (CH) Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
CA2902613A1 (en) * 2013-03-14 2014-10-02 Pharmacyclics Llc Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors

Also Published As

Publication number Publication date
JP2021105048A (ja) 2021-07-26
CA2976755A1 (en) 2016-08-25
JP2018507216A (ja) 2018-03-15
WO2016132303A1 (en) 2016-08-25
AU2019200876A1 (en) 2019-02-28
ZA201705363B (en) 2019-07-31
US20200093795A1 (en) 2020-03-26
BR112017017594A2 (pt) 2018-05-08
RU2017132445A3 (es) 2019-09-23
IL253895A0 (en) 2017-10-31
CL2017002116A1 (es) 2018-05-18
CN107249596A (zh) 2017-10-13
RU2017132445A (ru) 2019-03-20
SG11201706521XA (en) 2017-09-28
AU2016221327A1 (en) 2017-08-31
MA41544A (fr) 2017-12-26
US20230181529A1 (en) 2023-06-15
RU2729425C2 (ru) 2020-08-06
US20190388393A1 (en) 2019-12-26
PH12017501494A1 (en) 2018-01-29
EP3258933A1 (en) 2017-12-27
KR20170118798A (ko) 2017-10-25
TN2017000356A1 (en) 2019-01-16
TW201630602A (zh) 2016-09-01
AU2019200876B2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX2018003472A (es) Moduladores de la expresion de kras.
GB2544906B (en) Devices for treating vestibular and other medical impairments.
MX2017014163A (es) Moduladores de k-ras.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
TW201713333A (en) Methods of treating a neurodegenerative disease
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
PH12017500933A1 (en) Sublingual administration of riluzole
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PL3280392T3 (pl) Schematy dawkowania amisulprydu w leczeniu nudności i wymiotów
NZ722600A (en) Methods of treating mild brain injury
MX2017012553A (es) Compuestos espirociclicos.
MX2018002554A (es) Combinaciones de inhibidores de btk para tratar mieloma multiple.
MX2017014436A (es) Compuestos biciclicos.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
GB201615455D0 (en) Last dose protection
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12017501494A1 (en) Panobinostat dosages for multiple myeloma
EP3151823A4 (en) Fixed dose combination for pain relief without edema
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2019003366A (es) Ajuste de la dosis.